AAPL 143.43 +0.48999 0.34279436FB 357.48 +1.78 0.50042135GOOG 2792.93 +12.5898 0.45281667MSFT 294.8 +0.5 0.16989467NVDA 212.46 +1.33 0.6299445WBA 48.02 -0.380001 -0.78512615ZNGA 7.66 -0.0799999 -1.0335908
AAPL 143.43 +0.48999 0.34279436FB 357.48 +1.78 0.50042135GOOG 2792.93 +12.5898 0.45281667MSFT 294.8 +0.5 0.16989467NVDA 212.46 +1.33 0.6299445WBA 48.02 -0.380001 -0.78512615ZNGA 7.66 -0.0799999 -1.0335908

Financial Summary RDHL Quote RedHill Bio

RedHill Biopharma Ltd. Quote

RedHill Biophar (RDHL)

4.81 0.26 Healthcare
Stock Performance rating :
Recommendation :
Strong Sell
Score :
C-
Symbol RDHL
Price 4.81
Beta 1.40
Vol Avg 777.56 K
Mkt cap 226.94 M
Shares 13
Last Div Not Available
Div Yield 0.00%
DCF Unlevered 0.00
DCF Levered 0.00
ROE -92.06% Strong Sell
ROA -78.38% Strong Sell
Operating Margin -Infinity% Strong Sell
Debt/Equity 19.05% Neutral
P/E -2.16 Sell
P/B 0.99 Buy
All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Income Statement
Year 20142015201620172018
Revenue 7 0 0 0 0
COGS 1 0 0 2 3
GrossProfit 6 0 0 2 6
Depreciation (included in COGS) 0 0 0 0 0
StockBasedCompe (included in COGS) 2 1 2 2 3
ResearchAndDeve 13 18 25 33 25
SalesGeneralAnd 4 4 5 20 20
OperatingIncome -11 -22 -31 -51 -39
InterestExpense 0 0 0 0 0
OtherIncome 0 1 1 6 1
IncomeBeforeTax -11 -21 -29 -46 -39
ProvisionForInc 0 0 0 0 0
NetIncome -11 -21 -29 -46 -39
Balance Sheet
Year 20142015201620172018
CashAndCashEqui 6 22 54 16 29
ShortTermInvest 0 0 12 17 24
Cash 6 22 66 0 0
AccountReceivab 0 0 0 0 0
Inventories 0 0 0 0 0
DeferredIncomeT 0 0 0 0 0
OtherCurrentAss 17 37 0 14 0
TotalCurrentAss 26 61 68 52 57
PPE 0 0 0 0 1
AccumulatedDepr 0 0 0 0 0
NetPPE 0 0 0 0 0
EquityAndOtherI 0 0 0 0 0
Goodwill 0 0 0 0 0
IntangibleAsset 3 6 6 5 5
OtherLTAssets 0 0 0 0 0
TotalNonCurrent 3 6 6 6 6
TotalAssets 29 67 74 57 62
ShortTermDebt 0 0 0 0 0
AccountsPayable 0 0 0 0 0
TaxesPayable 0 0 0 0 0
AccruedLiabilit 0 3 3 0 0
DeferredRevenue 0 0 0 0 0
OtherCurrentLia 2 2 2 2 1
TotalCurrentLia 2 6 5 12 10
Debt 0 0 0 0 0
DeferredTaxesLi 0 0 0 0 0
DeferredRevenue 0 0 0 0 0
OtherLTLiabilit 2 1 6 0 1
TotalNonCurrent 2 1 6 0 1
TotalLiabilitie 4 7 12 12 11
CommonStock 0 0 0 1 1
AdditionalPaidI 65 121 151 177 220
RetainedEarning -42 -62 -90 -133 -169
AccumulatedOthe 2 1 1 0 0
TotalStockholde 25 60 63 45 51
TotalLiabilitie 29 67 74 57 62
Cash Flow Statement
Year 20142015201620172018
NetIncome -11 -21 -29 -46 -39
Depreciation 0 0 0 0 0
DeferredIncomeT 0 0 0 0 0
StockBasedCompe 2 1 2 2 3
AccountsReceiva 0 0 0 -1 1
InventoryCS 0 0 0 -1 0
AccountsPayable 0 0 0 5 -1
OtherWorkingCap -1 2 0 0 0
OtherNonCashIte 0 -1 -1 -6 0
NetCashProvided -12 -18 -28 -45 -34
InvestmentsInPP 0 0 0 0 0
AcquisitionsNet 0 0 0 0 0
PurchasesOfInve -7 0 -12 -22 -7
SalesMaturities 0 0 0 18 12
PurchasesOfInta -1 -2 0 -1 0
OtherInvestingA -10 -20 37 -13 0
NetCashUsedForI -18 -21 24 -19 5
DebtIssued 0 0 0 0 0
DebtRepayment 0 0 0 0 0
CommonStockIssu 19 55 36 22 42
CommonStockRepu 0 0 0 0 0
DividendPaid 0 0 0 0 0
OtherFinancingA 5 0 0 3 0
NetCashProvided 24 55 36 26 42
NetChangeInCash -6 16 32 -37 13
CashAtBeginning 12 6 22 54 16
CashAtEndOfPeri 6 22 54 16 29
Retained Earnings
Year 20142015201620172018
RetainedEarning ----42-62
NetIncome ---11-21-29
StockDividend --534157
DividendPaid -----
RetainedEarning ---42-62-90
Property Plant and Equipment Schedule
Year 20142015201620172018
NetPPE -----
DeprAnnual 0----
CapitalExpendit 00120
NetPPE -----
Intangible and Goodwill Schedule
Year 20142015201620172018
intAndGW 0--36
Amortization 0----
NewPurchases 0-33-
intAndGW --366
Company Profile

CEO

Mr. Dror Ben-Asher

Sector

Healthcare

Industry

Drug Manufacturers—Specialty & Generic

Exchange

Nasdaq Capital Market

Description

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.